Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Aug 1;208(3):220-222.
doi: 10.1164/rccm.202306-0978ED.

Leveraging Omics to Predict Chronic Obstructive Pulmonary Disease Exacerbations: The "Immunome"

Francesca Polverino  1 , Ravi Kalhan  2
Affiliations
Editorial

Leveraging Omics to Predict Chronic Obstructive Pulmonary Disease Exacerbations: The "Immunome"

Francesca Polverino et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Leveraging omic endotyping to enable personalized medicine in chronic obstructive pulmonary disease (COPD). Individuals with COPD share many clinical traits that allow a common disease diagnosis, yet this shared phenotype accounts for different types of pathobiology (i.e., endotypes). Important steps in patient endotyping are 1) minimally invasive sampling of patient diseased tissue; 2) molecular and cellular characterization of diseased samples with analyses of bulk and or scRNAseq, metabolomic and proteomic processes, and radiological features to identify pathobiological mechanisms in the disease group (ultimately, this step will require validation of the findings in lung tissue from independent cohorts); 3) integration of multiscale, multi-omic data with machine-learning approaches; and 4) separation of patients into endotype groups on the basis of the presence and/or level of one or more of these pathobiology types. The endotype of the patient with COPD forms the basis for personalized clinical disease management. scRNAseq = single-cell RNA sequencing.
See this image and copyright information in PMC

Comment on

References

    1. Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 report: GOLD executive summary. Am J Respir Crit Care Med . 2023;207:819–837. - PMC - PubMed
    1. Stolz D, Mkorombindo T, Schumann DM, Agusti A, Ash SY, Bafadhel M, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet . 2022;400:921–972. - PMC - PubMed
    1. Sidhaye VK, Nishida K, Martinez FJ. Precision medicine in COPD: where are we and where do we need to go? Eur Respir Rev . 2018;27:180022. - PMC - PubMed
    1. Regan EA, Hersh CP, Castaldi PJ, DeMeo DL, Silverman EK, Crapo JD, et al. Omics and the search for blood biomarkers in chronic obstructive pulmonary disease. Insights from COPDGene. Am J Respir Cell Mol Biol . 2019;61:143–149. - PMC - PubMed
    1. Stockley RA, Halpin DMG, Celli BR, Singh D. Chronic obstructive pulmonary disease biomarkers and their interpretation. Am J Respir Crit Care Med . 2019;199:1195–1204. - PubMed

MeSH terms